Effect of arachidonic acid-rich oil on lipids and arachidonate metabolites in ethanol- treated rats

2001 ◽  
Vol 64 (4-5) ◽  
pp. 273-279 ◽  
Author(s):  
M. Okita ◽  
T. Sasagawa ◽  
Y. Ohta ◽  
T. Kaneyuki ◽  
K Suzuki
Keyword(s):  
Arachidonic Acid ◽  
Arachidonate Metabolites

Cytochrome P-450 arachidonate metabolites affect ion fluxes in rabbit medullary thick ascending limb

1994 ◽  
Vol 266 (6) ◽  
pp. C1775-C1782 ◽  
Author(s):  
B. Escalante ◽  
D. Erlij ◽  
J. R. Falck ◽  
J. C. McGiff
Keyword(s):  
Arachidonic Acid ◽  
Mechanism Of Action ◽  
Alkali Cation ◽  
Eicosatetraenoic Acid ◽  
Thick Ascending Limb ◽  
K Channels ◽  
Medullary Thick Ascending Limb ◽  
Arachidonate Metabolites ◽  
Rate Limiting ◽  
Cytochrome P 450

The medullary thick ascending limb of Henle's loop (mTALH) of the rabbit metabolizes arachidonic acid (AA) via a cytochrome P-450 (P-450) monooxygenase pathway to several products, of which the principal are 20-hydroxy-5,8,11,14-eicosatetraenoic acid (20-HETE) and 1,20-eicosatetraenedioic acid (20-COOH-AA). To understand their mechanism of action on alkali cation metabolism in mTALH cells, we have compared their effects with those of ouabain and furosemide. Incubation of rabbit isolated mTALH cells with either 1 mM ouabain or furosemide decreased K+ content from a control of 1,015 +/- 51 peq/micrograms protein to 717 +/- 41 and to 548 +/- 48 peq/micrograms protein, respectively, whereas they had opposite effects on Na+ content; from a control of 138 +/- 22 peq/micrograms protein, ouabain increased Na+ content to 357 +/- 37 peq/micrograms protein, and furosemide decreased it to 64 +/- 23 peq/micrograms protein. Preincubation with either 20-HETE (1 microM) or 20-COOH-AA (1 microM) decreased Na+ and K+, resembling furosemide in their effects on Na+ and K+ content. In other experiments we used monensin-treated cells to determine 86Rb uptake under conditions in which Na+ entry into the cell was not rate limiting. Under these conditions ouabain still inhibited 86Rb uptake, and the effect of AA was blocked. A major action of AA metabolites on Na(+)-K(+)-adenosinetriphosphatase was thereby excluded. Furthermore, AA metabolites did not inhibit Ba(2+)-sensitive 86Rb efflux, indicating that they do not act through K+ channels.(ABSTRACT TRUNCATED AT 250 WORDS)

Polarity of arachidonic acid metabolism by bovine aortic endothelial cell monolayers

1987 ◽  
Vol 253 (5) ◽  
pp. H1177-H1183
Author(s):  
D. M. Shasby ◽  
L. L. Stoll ◽  
A. A. Spector
Keyword(s):  
Arachidonic Acid ◽  
Arachidonic Acid Metabolism ◽  
Biologically Active ◽  
Bovine Aortic Endothelial Cell ◽  
Ionophore A23187 ◽  
Vascular Events ◽  
Aortic Endothelial Cells ◽  
Cell Monolayers ◽  
Arachidonate Metabolites ◽  
Aortic Endothelial

Monolayers of bovine aortic endothelial cells cultured on micropore filters were used to determine the polarity of endothelial uptake, release, and transfer of arachidonic acid and some of its metabolites. Uptake and spontaneous release of arachidonic acid were more rapid at the luminal than at the interstitial surface. Transfer of arachidonic acid was more rapid from the luminal to the interstitial compartment than from the interstitial to the luminal compartment. After stimulation with the ionophore A23187, monolayers released arachidonate metabolites, including prostacyclin, to both the luminal and the interstitial compartments. The ability of the endothelium to rapidly take up and release arachidonic acid from the luminal surface and the ability to release biologically active eicosanoids to both the lumen and interstitium could be important for endothelial modulation of vascular events.

scholarly journals Leukotriene B4 synthesis and metabolism by neutrophils and granule-free cytoplasts

1986 ◽  
Vol 233 (2) ◽  
pp. 583-588 ◽  
Author(s):  
K A Haines ◽  
K N Giedd ◽  
G Weissmann
Keyword(s):  
Arachidonic Acid ◽  
Plasma Membrane ◽  
Leukotriene B4 ◽  
Ionophore A23187 ◽  
Tetraenoic Acid ◽  
Exogenous Arachidonic Acid ◽  
Neutrophil Degranulation ◽  
Arachidonate Metabolites

Leukotriene B4 [LTB4, (5S,12R)-hydroxyeicosa-6,14-cis-8,10-trans-tetraenoic acid], a potent mediator of inflammation, is released from neutrophils by agonists that provoke degranulation of the cell. To examine whether degranulation is a necessary requirement for synthesis and metabolism of LTB4 (or of other arachidonate metabolites), we prepared neutrophil-derived cytoplasts (neutroplasts), organelle-depleted vesicles of cytoplasm surrounded by the plasma membrane. In the presence of extracellular Ca2+ with or without exogenous arachidonic acid (150 microM), neutroplasts were exposed to the Ca2+ ionophore A23187 (10 microM) and the resultant lipoxygenation products of arachidonate were determined. Neutrophils metabolize arachidonic acid to 5-HETE greater than 15-HETE greater than LTB4 greater than all-trans-LTB4 isomers. Neutroplast products of arachidonate lipoxygenation were 15-HETE greater than 5-HETE greater than LTB4 greater than all-trans-LTB4 isomers. Neutroplasts, like neutrophils, were capable of converting LTB4 into its 20-hydroxy and 20-carboxy metabolites. Finally, neutroplasts could utilize intrinsic arachidonate, since the neutroplasts synthesized LTB4 (30 pmol/mg of protein) in the absence of added arachidonic acid. The data demonstrate that neutrophil degranulation is not required for synthesis or metabolism of LTB4 by neutrophils.

Metabolism of arachidonic acid by pancreatic acini: relation to amylase secretion

1982 ◽  
Vol 242 (5) ◽  
pp. G493-G497
Author(s):  
W. F. Stenson ◽  
E. Lobos
Keyword(s):  
Arachidonic Acid ◽  
Guinea Pig ◽  
Thin Layer ◽  
Prostaglandin E2 ◽  
Amylase Secretion ◽  
Pancreatic Acini ◽  
Arachidonate Metabolites ◽  
Stimulus Secretion Coupling ◽  
Layer Chromatography

Isolated guinea pig pancreatic acini were incubated with exogenous [14C]arachidonic acid (10 microM) at 37 degrees C for 3 min. The lipids were extracted and separated by thin-layer chromatography. Radiolabeled metabolites were identified by comigration with standards: 0.024% of the recovered radioactivity comigrated with prostaglandin E2 (PGE2), 0.016% comigrated with PGF2 alpha, 4.9% was incorporated into triglycerides, 1.8% was incorporated into phospholipids, and 93.2% remained as arachidonic acid. The synthesis of PGE2 and PGF2 alpha was inhibited by indomethacin (ID50, 30 nM). Simultaneous addition of carbachol or caerulein with the [14C]arachidonic acid did not alter the metabolism of the arachidonate. Further studies were done on the role of arachidonate metabolites in the secretion of amylase. Exogenously added PGE2 and PGF2 alpha (0.3-100 nM) did not induce amylase secretion from isolated acini. Incubation of isolated acini with indomethacin (0.1-28 microM) did not inhibit the release of amylase induced by carbachol or caerulein. From these data, we conclude that isolated guinea pig pancreatic acini are capable of converting a small percentage of exogenous arachidonate to PGE2 and PGF2 alpha. However, there is no evidence for a role of these compounds in stimulus-secretion coupling.

Increased Response to Arachidonic Acid and U-46619 and Resistance to Inhibitory Prostaglandins in Patients with Chronic Myeloproliferative Disorders

1988 ◽  
Vol 59 (01) ◽  
pp. 073-076 ◽  
Author(s):  
Sergio Cortelazzo ◽  
Monica Galli ◽  
Donatella Castagna ◽  
Piera Viero ◽  
Giovanni de Gaetano ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Arachidonic Acid ◽  
Platelet Aggregation ◽  
Myeloproliferative Disorders ◽  
Bone Marrow Stem Cell ◽  
Healthy Controls ◽  
Aggregation Response ◽  
Thrombotic Complications ◽  
Cyclic Endoperoxide ◽  
Marrow Stem Cell

SummaryIn patients with myeloproliferative disorders (MPD) a group of related diseases of the bone marrow stem cell and recurrent haemorrhagic and/or thrombotic complications, the production of aggregating prostaglandins (PGs) may be normal or slightly reduced, while PGI2 production is normal. However, MPD platelet sensitivity to antiaggregatory PGs is still unknown.We studied the potency of PGD2, PGI2 and PGEi as inhibitors of platelet aggregation induced by threshold aggregating concentrations of arachidonic acid and U-46619-analogue of the cyclic endoperoxide PGH2 in 20 patients with MPD in comparison with healthy controls, with the aim of evaluating the sensitivity of MPD platelets to antiaggregatory PGs. In these patients platelet prostanoid metabolism was normal. However, the functional response of platelets to aggregating and antiaggregating prostanoids was shifted towards potentially increased platelet aggregation response. These findings could have a clinical relevance in view of the haemostatic and thrombotic complications so frequent in MPD.

Dose-Response Aggregometry in Maternal/Neonatal Platelets

1988 ◽  
Vol 60 (02) ◽  
pp. 314-318 ◽  
Author(s):  
A M A Gader ◽  
H Bahakim ◽  
F A Jabbar ◽  
A L Lambourne ◽  
T H Gaafar ◽  
...  
Keyword(s):  
Arachidonic Acid ◽  
Dose Response ◽  
Lag Phase ◽  
Phase Slope ◽  
Multiple Doses ◽  
Nonpregnant Adult ◽  
Aggregation Of Platelets

SummaryThe aggregation of platelets collected from maternal/neonatal pairs (n = 240) at the time of childbirth, was studied in response to multiple doses of ADP, collagen, arachidonic acid and ristocetin. Similar responses were obtained from healthy nonpregnant adult controls for comparison. The lag phase, slope of the aggregation curves as well as maximum aggregation (MA%) were recorded and analysed. Neonatal and adult platelets exhibited more enhanced responses to decreasing doses of ADP, arachidonic acid and ristocetin, than maternal platelets. These enhanced responses were exhibited more consistantly in the slopes of the aggregation curves than in MA%. Although neonatal platelets have shown longer lag phase in their responses to collagen, the rate of the aggregation reaction was significantly faster than maternal platelets, with no differences in MA%. These results contradict many previous reports suggesting impaired aggregation responses of neonatal platelets to these agonist. The possible reasons for these contradictions were discussed.

Involvement of Cyclooxygenase- and Lipoxygenase-Mediated Conversion of Arachidonic Acid in Controlling Human Vascular Smooth Muscle Cell Proliferation

1990 ◽  
Vol 63 (02) ◽  
pp. 291-297 ◽  
Author(s):  
Herm-Jan M Brinkman ◽  
Marijke F van Buul-Worteiboer ◽  
Jan A van Mourik
Keyword(s):  
Cell Proliferation ◽  
Arachidonic Acid ◽  
Smooth Muscle ◽  
Vascular Smooth Muscle ◽  
Smooth Muscle Cells ◽  
Smooth Muscle Cell ◽  
Muscle Cell ◽  
Vascular Smooth Muscle Cell ◽  
Muscle Cells ◽  
Smooth Muscle Cell Proliferation

SummaryWe observed that the growth of human umbilical arterysmooth muscle cells was inhibited by the phospholipase A2 inhibitors p-bromophenacylbromide and mepacrine. Thesefindings suggest that fatty acid metabolism might be integrated in the control mechanism of vascular smooth muscle cell proliferation. To identify eicosanoids possibly involved in this process, we studied both the metabolism of arachidonic acid of these cells in more detail and the effect of certain arachidonic acid metabolites on smooth muscle cells growth. We found no evidence for the conversion of arachidonic acid via the lipoxygenase pathway. In contrast, arachidonic acid was rapidly converted via the cyclooxy-genase pathway. The following metabolites were identified: prostaglandin E2 (PGE2), 6-keto-prostaglandin F1α (6-k-PGF1α), prostaglandin F2α (PGF2α), 12-hydroxyheptadecatrienoic acid (12-HHT) and 11-hydroxyeicosatetetraenoic acid (11-HETE). PGE2 was the major metabolite detected. Arachidonic acid metabolites were only found in the culture medium, not in the cell. After synthesis, 11-HETE was cleared from the culture medium. We have previously reported that PGE2 inhibits the serum-induced [3H]-thymidine incorporation of growth-arrested human umbilical artery smooth muscle cells. Here we show that also 11-HETEexerts this inhibitory property. Thus, our data suggeststhat human umbilical artery smooth muscle cells convert arachidonic acid only via the cyclooxygenase pathway. Certain metabolites produced by this pathway, including PGE2 and 11-HETE, may inhibit vascular smooth muscle cell proliferation.

Chlorobutanol, a Preservative of Desmopressin, Inhibits Human Platelet Aggregation and Release In Vitro

1990 ◽  
Vol 64 (03) ◽  
pp. 473-477 ◽  
Author(s):  
Shih-Luen Chen ◽  
Wu-Chang Yang ◽  
Tung-Po Huang ◽  
Shiang Wann ◽  
Che-ming Teng
Keyword(s):  
Arachidonic Acid ◽  
Platelet Aggregation ◽  
Atp Release ◽  
Free Calcium ◽  
Dependent Manner ◽  
Antiplatelet Effect ◽  
Human Platelet Aggregation ◽  
Acid Pathway ◽  
Arachidonic Acid Pathway

SummaryTherapeutic preparations of desmopressin for parenteral use contain the preservative chlorobutanol (5 mg/ml). We show here that chlorobutanol is a potent inhibitor of platelet aggregation and release. It exhibited a significant inhibitory activity toward several aggregation inducers in a concentration- and time-dependent manner. Thromboxane B2 formation, ATP release, and elevation of cytosolic free calcium caused by collagen, ADP, epinephrine, arachidonic acid and thrombin respectively were markedly inhibited by chlorobutanol. Chlorobutanol had no effect on elastase- treated platelets and its antiplatelet effect could be reversed. It is concluded that the antiplatelet effect of chlorobutanol is mainly due to its inhibition on the arachidonic acid pathway but it is unlikely to have a nonspecitic toxic effect. This antiplatelet effect of chlorobutanol suggests that desmopressin, when administered for improving hemostasis, should not contain chlorobutanol as a preservative.

Synergistic Antiplatelet Effect of Ridogrel, a Combined Thromboxane Receptor Antagonist and Thromboxane Synthase Inhibitor, and UDCG-212, a cAMP-Phosphodiesterase Inhibitor

1993 ◽  
Vol 70 (05) ◽  
pp. 822-825 ◽  
Author(s):  
B Hoet ◽  
J Arnout ◽  
H Deckmyn ◽  
J Vermylen
Keyword(s):  
Arachidonic Acid ◽  
Platelet Aggregation ◽  
Receptor Antagonist ◽  
Phosphodiesterase Inhibitor ◽  
Camp Phosphodiesterase ◽  
Thromboxane Receptor ◽  
Thromboxane Synthase Inhibitor ◽  
Thromboxane Receptor Antagonist ◽  
Synthase Inhibitor ◽  
Camp Levels

SummaryRidogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor (1), inhibits platelet aggregation. Following stimulation with arachidonic acid, cAMP-levels are increased in human platelets preincubated with ridogrel, this is due to the known reorientation of the metabolism of the formed endoperoxides towards adenylate cyclase stimulating prostaglandins.Pretreatment of resting platelets with UDCG-212, a cAMP-phosphodiesterase inhibitor (2), also inhibits platelet aggregation induced by arachidonic acid, concomitant with an increase in cAMP levels, due to an inhibition of its breakdown. Under basal conditions, cAMP also is increased.By combining the two drugs, a more than additive action was observed on platelet aggregation and on both resting and stimulated platelet cAMP content. The appropriate combination may result in a more effective antiplatelet strategy.

Sign in / Sign up

Export Citation Format

Share Document